Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
J Clin Pharmacol ; 60 Suppl 2: S74-S85, 2020 12.
Article in English | MEDLINE | ID: mdl-33274517

ABSTRACT

Every woman, if she lives long enough, will transition into menopause, and as the US population ages, women will be spending more time in a postmenopausal state than before. For postmenopausal women, the decision to initiate menopausal hormone therapy should be individualized. A thorough evaluation of the patient's cardiovascular, venous thromboembolic, cancer, and fracture risk should be considered along with the woman's quality of life. Hormone therapy exerts its therapeutic effects on vasomotor symptoms, the skeleton, and the genitourinary system independent of age since menopause and these benefits are lost once hormone therapy is stopped. Here we review the pharmacologic properties dose, formulation, mode of administration, timing of initiation, and duration of hormonal therapies in regard to optimizing benefit and minimizing risk to the patient. This discussion will focus on the effects of common hormonal therapies including estrogen (local and systemic), progesterone, estrogen receptor agonist/antagonist, and local dehydroepiandrosterone and include a brief review of compounded bioidentical hormone therapy.


Subject(s)
Estrogen Replacement Therapy/methods , Menopause/drug effects , Dehydroepiandrosterone/administration & dosage , Estrogens/administration & dosage , Estrogens/adverse effects , Estrogens/metabolism , Estrogens/pharmacokinetics , Female , Female Urogenital Diseases/drug therapy , Humans , Progestins/administration & dosage , Progestins/adverse effects , Progestins/metabolism , Progestins/pharmacokinetics , Receptors, Estrogen/drug effects , Testosterone/administration & dosage
2.
J Oncol Pract ; 15(7): 363-370, 2019 07.
Article in English | MEDLINE | ID: mdl-31291563

ABSTRACT

Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM). GSM can decrease quality of life and is undertreated by oncologists because of fear of cancer recurrence, specifically when considering treatment with vaginal estrogen therapy because of unknown levels of systemic absorption of estradiol. In this article, we review the available literature for treatment of GSM in patients with breast cancer and survivors, including nonhormonal, vaginal hormonal, and systemic hormonal therapy options. First-line treatment includes nonhormonal therapy with vaginal moisturizers, lubricants, and gels. Although initial studies showed significant improvement in symptoms, the US Food and Drug Administration recently issued a warning against CO2 laser therapy for treatment of GSM until additional studies are conducted. In severe or refractory GSM, after discussing risks and benefits of vaginal hormonal therapy, the low-dose 10-µg estradiol-releasing intravaginal tablet or lower-dose 4 µg estrogen vaginal insert and intravaginal dehydroepiandrosterone (prasterone) are options for treatment, because studies show minimal elevation in serum estradiol levels and significant improvement in symptoms. The decision to offer vaginal estrogen therapy must be individualized and made jointly with the patient and her oncologist.


Subject(s)
Breast Neoplasms , Cancer Survivors , Female Urogenital Diseases/therapy , Menopause , Aromatase Inhibitors/therapeutic use , Breast Neoplasms/drug therapy , Dehydroepiandrosterone/therapeutic use , Estrogens/therapeutic use , Female , Humans , Laser Therapy , Lubricants/therapeutic use , Syndrome , Testosterone/therapeutic use
3.
Cleve Clin J Med ; 85(11): 860, 2018 11.
Article in English | MEDLINE | ID: mdl-30395529

ABSTRACT

In the article by A.C. Moreno, S.K. Sikka, and H.L. Thacker, Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available, Cleve Clin J Med 2018; 85(10):760-766, doi:10.3949/ccjm.85a.17108, Table 2 incorrectly stated that prasterone is contraindicated in women with known or suspected breast cancer. This correction has been made online as follows. "Warning: Estrogen is a metabolite of prasterone; use of exogenous extrogen is contraindicated in women with known or suspected breast cancer; prasterone has not been studied in women with a history of breast cancer."

4.
Cleve Clin J Med ; 85(10): 760-766, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30289755

ABSTRACT

When treating the genitourinary syndrome of menopause (GSM) in women with breast cancer or at high risk of breast cancer, clinicians must balance the higher cancer risks associated with hormonal treatments against the severity of GSM symptoms, which can be exacerbated by breast cancer treatments. Options for patients who need hormonal therapy include locally applied estrogens, dehydroepiandrosterone (DHEA), and estrogen receptor agonists/antagonists, which vary in their impact on breast cancer risk.


Subject(s)
Breast Neoplasms/therapy , Estrogen Replacement Therapy/methods , Estrogens/administration & dosage , Female Urogenital Diseases/drug therapy , Long Term Adverse Effects/drug therapy , Cancer Survivors , Female , Female Urogenital Diseases/etiology , Humans , Long Term Adverse Effects/etiology , Menopause , Syndrome
5.
Cleve Clin J Med ; 84(6): 463-470, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28628428

ABSTRACT

Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.


Subject(s)
Bone Diseases, Metabolic/drug therapy , Breast Neoplasms/drug therapy , Estrogens/pharmacology , Hot Flashes/drug therapy , Menopause/physiology , Selective Estrogen Receptor Modulators/pharmacology , Drug Therapy, Combination , Female , Humans , Treatment Outcome
6.
Cleve Clin J Med ; 84(2): 151-158, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28198687

ABSTRACT

Urinary incontinence is common, underreported, and undertreated. Primary care physicians should be comfortable discussing urinary incontinence with their female patients and managing it with conservative treatment.


Subject(s)
Urinary Incontinence/therapy , Adrenergic beta-3 Receptor Antagonists/therapeutic use , Biofeedback, Psychology , Cholinergic Antagonists/therapeutic use , Combined Modality Therapy , Diet Therapy , Exercise Therapy , Female , Humans , Pessaries , Primary Health Care/methods , Urinary Incontinence/diagnosis , Weight Loss
7.
8.
Implant Dent ; 25(4): 478-84, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26963744

ABSTRACT

PURPOSE: To compare bone thickness buccal to the teeth in the esthetic zone of postmenopausal women, premenopausal women, younger men and older men. METHODS: Retrospective data were randomly selected from 4 groups: 59 premenopausal women, 60 postmenopausal women, 60 men less than age 50, and 60 men more than 50. Half-root and bone crest landmarks were identified on each participant's cone beam computed tomography for teeth 7 to 10 and 23 to 26. Buccal bone thickness was measured by calibrated examiners. Group averages were calculated and compared between groups using analysis of variance (P < 0.05). RESULTS: When comparing premenopausal to postmenopausal women and postmenopausal women to older men, anterior bone thickness was significantly different for tooth maxillary and mandibular lateral incisors and overall maxillary and mandibular central incisors. In addition, significant differences were observed between these groups within the maxilla comparing lateral incisors, central incisors (P < 0.05), and within the mandible when comparing lateral and central incisors at (P < 0.05) at bone crest and half-root, respectively. CONCLUSION: Buccal bone in the anterior esthetic zone bone is thin in all segments of the population, but significantly thinner in postmenopausal women. In this cohort, when anterior implants are planned, it is essential to make informed treatment planning decisions. Strategies are available to manage the thinner bony housing, but require further research specific to this growing consumer cohort.


Subject(s)
Alveolar Process/anatomy & histology , Esthetics, Dental , Menopause , Adult , Age Factors , Alveolar Process/diagnostic imaging , Cone-Beam Computed Tomography , Female , Humans , Incisor/anatomy & histology , Incisor/diagnostic imaging , Male , Middle Aged , Retrospective Studies , Sex Factors , Tooth/anatomy & histology , Tooth/diagnostic imaging
9.
J Womens Health (Larchmt) ; 24(5): 336-40, 2015 May.
Article in English | MEDLINE | ID: mdl-25884348

ABSTRACT

While Women's Health (WH) Fellowships have been in existence since 1990, knowledge of their existence seems limited. Specialized training in WH is crucial to educate leaders who can appropriately integrate this multidisciplinary field into academic centers, especially as the demand for providers confident in the areas of contraception, perimenopause/menopause, hormone therapy, osteoporosis, hypoactive sexual desire disorder, medical management of abnormal uterine bleeding, office based care of stress/urge incontinence, and gender-based medicine are increasing popular and highly sought after. WH fellowship programs would benefit from accreditation from the American Board of Medical Subspecialties and from the American College of Graduate Medical Education, as this may allow for greater recruitment, selection, and training of future leaders in WH. This article provides a current review of what WH trained physicians can offer patients, and also highlights the added value that accreditation would offer the field. Ultimately, accrediting WH fellowships will improve women's health medical education by creating specialists that can serve as academic leaders to help infuse gender specific education in primary residencies, as well as serve as consultants and leaders, and promote visibility and prestige of the field.


Subject(s)
Accreditation/standards , Education, Medical, Graduate/legislation & jurisprudence , Fellowships and Scholarships , Patient Care Team , Women's Health , Female , Humans , Internship and Residency , Physicians
10.
Menopause ; 22(1): 75-8, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24983272

ABSTRACT

OBJECTIVE: This study aims to compare periodontitis severity in postmenopausal women whose FRAX (World Health Organization Fracture Risk Assessment Tool) scores indicate a major risk for osteoporotic fracture (OPF) versus controls. METHODS: Participant charts from the Case/Cleveland Clinic Postmenopausal Wellness Collaboration 853-sample database were selected based on the following inclusion criteria: (1) aged between 51 and 80 years; (2) menopause for more than 1 year but less than 10 years; (3) nonsmoker; (4) hemoglobin A1c less than 7; and (5) no glucocorticoid, hormone, RANKL (receptor activator of nuclear factor-κB ligand) inhibitor, or bisphosphonate therapy within 5 years. FRAX score was calculated, and participants were organized into two groups: women with major OPF risk (FRAX scores >20%) and controls. Periodontal data were obtained from the charts. T test was used to assess differences in periodontal parameters between groups. RESULTS: Ninety participants had FRAX scores higher than 20% and were considered to have high OPF risk; 98 participants served as controls. Probing depth (mean [SD], 2.75 [0.66] vs 2.2 [0.57]), clinical attachment loss (3.15 [0.78] vs 2.73 [0.66]), alveolar bone height (0.58 [0.03] vs 0.60 [0.02]), and tooth loss (5.6 [1.96] vs 3.84 [1.94]) were significantly different between groups, whereas plaque score and bleeding on probing were not. CONCLUSIONS: Postmenopausal women whose FRAX scores suggest major OPF risk have significantly more severe periodontitis endpoints than controls even though oral hygiene scores do not significantly differ. These findings suggest to clinicians treating women after menopause that referral to a periodontist for disease screening may be appropriate for those women with high fracture risk based on FRAX scores.


Subject(s)
Osteoporotic Fractures , Periodontitis/diagnosis , Postmenopause/physiology , Risk Assessment , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/complications , Periodontitis/etiology , Periodontitis/physiopathology , Risk Factors , Tooth Loss/etiology
11.
J Womens Health (Larchmt) ; 23(8): 642-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25111856

ABSTRACT

After the publication of the Women's Health Initiative, attitudes towards management of menopausal symptoms changed dramatically. One alternative that has received much media attention is the use of bioidentical hormone therapy (BHT). The media and celebrity endorsements have promoted a number of misconceptions about the risks and benefits associated with the various forms of BHT. This article will review the available evidence regarding the safety and efficacy of BHT in comparison to conventional hormone therapy. We will also review several cases seen in our midlife women's referral clinics, which demonstrate concerns for the safety and efficacy of BHT, including unexplained endometrial cancer in otherwise healthy BHT users. Due to the lack of sufficient data to support the efficacy or safety of BHT, we recommend the use of United States Food and Drug Administration-approved regimens in the management of menopausal symptoms.


Subject(s)
Biosimilar Pharmaceuticals/adverse effects , Drug Compounding/adverse effects , Endometrial Neoplasms/pathology , Estrogen Replacement Therapy/adverse effects , Menopause/drug effects , Women's Health , Aged , Biosimilar Pharmaceuticals/administration & dosage , Endometrial Neoplasms/etiology , Estradiol/administration & dosage , Estradiol/adverse effects , Estriol/administration & dosage , Estriol/adverse effects , Estrogen Replacement Therapy/methods , Female , Humans , Middle Aged , Progesterone/administration & dosage , Progesterone/adverse effects , Therapeutic Equivalency , Treatment Outcome , United States , United States Food and Drug Administration
12.
Womens Health (Lond) ; 10(2): 147-54, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24601805

ABSTRACT

In the USA, over 30 million women are in or near menopause. Menopause is associated with a cluster of issues. Vasomotor symptoms (VMS) are the number one complaint of most menopausal women. VMS are disruptive to women during the day and at night, which leads to poor sleep, anxiety, depression and poor concentration. Up until now, the only US FDA-approved medication for moderate-to-severe VMS was hormone therapy. Hormone therapy may not be appropriate for all women. Many drugs are used off-label to treat VMS. The most often used agents are agents that are FDA-approved medications, such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. The pharmaceutical company, Noven Pharmaceuticals (FL, USA), has studied paroxetine mesylate 7.5 mg, previously known as low-dose mesylate salt of paroxetine, specifically to treat moderate-to-severe VMS in postmenopausal women. Paroxetine is a selective serotonin reuptake inhibitor, and is thought to help decrease VMS by regulating body temperature via neurotransmitters. Paroxetine is approved to treat various psychiatric disorders, but is used at much higher doses (20-60 mg/day).


Subject(s)
Hot Flashes/drug therapy , Paroxetine/therapeutic use , Postmenopause/physiology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sweating/physiology , Vasomotor System/physiopathology , Body Temperature Regulation , Female , Hot Flashes/physiopathology , Humans , Middle Aged
14.
Cleve Clin J Med ; 79(3): 207-12, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22383556

ABSTRACT

As health care providers, we must engage our female patients in a dialogue about their contraceptive and fertility decisions. Empowering and educating our patients about their bodies' hormones, the menstrual cycle, and the risk of unintended pregnancy are central to effective contraceptive counseling. Selecting an appropriate method for a patient and her medical profile is rewarding and challenging in view of new medications, novel delivery systems, and evolving research.


Subject(s)
Contraception/methods , Family Planning Services/methods , Health Knowledge, Attitudes, Practice , Women's Health , Adult , Contraception/instrumentation , Contraceptives, Oral , Female , Folic Acid , Humans , Hypertension , Male , Mental Disorders , Middle Aged , Young Adult
15.
Cleve Clin J Med ; 78(12): 829-36, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22135273

ABSTRACT

Many women are turning to bioidentical hormone therapy on the basis of misconceptions and unfounded claims, eg, that this therapy can reverse the aging process and that it is more natural and safe than approved hormone therapy. The aim of this article is to clarify some of the misconceptions.


Subject(s)
Estrogen Replacement Therapy/adverse effects , Therapeutic Misconception , Drug Compounding , Female , Humans
16.
J Womens Health (Larchmt) ; 20(7): 1007-16, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21675874

ABSTRACT

BACKGROUND: Vasomotor symptoms (VMS); (hot flushes and night sweats) are the most common menopausal complaint for which women seek treatment. Several therapies can be considered to help manage these complaints. The objective of this review is to assess the risks and benefits of available and emerging therapeutic options for the management of menopausal VMS. METHODS: A review of the literature was conducted based on relevant publications identified through a PubMed search for clinical trials of agents used in the treatment of VMS. RESULTS: Hormone therapy (HT) remains the most effective treatment available, but there will always remain a need for nonhormonal options. Evidence does not support the efficacy of alternative or over-the-counter products, such as phytoestrogens and black cohosh, and their long-term safety is largely unknown. There is evidence supporting the efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the management of VMS from clinical trials of paroxetine, venlafaxine, and desvenlafaxine. Gabapentin appears to be effective, but the doses required may cause poor tolerability and reduced patient adherence. Data also suggest that clonidine has a modest effect at the expense of considerable adverse effects. CONCLUSIONS: Choosing an appropriate treatment approach for the management of VMS requires careful assessment of the riskbenefit ratio of each alternative, as well as individual patient preference.


Subject(s)
Hot Flashes/therapy , Menopause/drug effects , Perimenopause/drug effects , Vascular Diseases/therapy , Vasomotor System/physiopathology , Women's Health , Adrenergic alpha-Agonists/therapeutic use , Cyclohexanecarboxylic Acids/therapeutic use , Evidence-Based Medicine , Female , Humans , Life Style , Middle Aged , Phytotherapy/methods , Selective Serotonin Reuptake Inhibitors/therapeutic use
17.
Cleve Clin J Med ; 76(8): 467-75, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19652040

ABSTRACT

After menopause, women become more susceptible to periodontal disease. We believe the problem is due in large part to estrogen deficiency with resulting bone loss and inflammatory processes. Osteoporosis and periodontal disease are best diagnosed early so that treatment can be started sooner and fractures and tooth loss can be prevented.


Subject(s)
Menopause , Oral Health , Periodontal Diseases/etiology , Disease Susceptibility , Estrogens/deficiency , Female , Humans , Osteoporosis, Postmenopausal/complications
18.
J Womens Health (Larchmt) ; 18(6): 873-81, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19514830

ABSTRACT

BACKGROUND: Osteopenia/low bone mineral density (BMD) can lead to osteoporosis and is far more prevalent than osteoporosis. The National Osteoporosis Foundation (NOF) has recommendations for prevention and treatment of low BMD; however, the condition remains underrecognized and undertreated. We assessed practice patterns between physician knowledge of low BMD and prescribing of additional pharmacological therapies as defined by the NOF guidelines. METHODS: This is a retrospective, observational chart review of electronic medical records of 99 postmenopausal women aged > or =60 years with T-scores between -1.0 and -2.5 on baseline BMD done in 2003 at the Cleveland Clinic Women's Health Center. Counseling, advisement of weightbearing exercise, recommendation of calcium and vitamin D supplementation, and adequate pharmacological therapy in the form of bisphosphonates, hormone therapy, or selective estrogen receptor modulators (SERMs) were assessed. The management of bone specialists credentialed both by the International Society of Clinical Densitometry and the North American Menopause Society and non-bone specialists was also compared. RESULTS: Bone specialists were more likely than non-bone specialists to offer counseling in the form of letters, phone encounters, and follow-up office visits and recommend weightbearing exercises. Most physicians recommended calcium and vitamin D supplementation regardless of specialty. There is no significant difference in the prescribing of pharmacological agents vs. conservative measures for osteopenic postmenopausal women by non-bone specialists vs. bone specialists as defined by the NOF guidelines, such that non-bone specialists did not treat these women any less aggressively than did bone specialists. CONCLUSIONS: Osteopenia is adequately managed in our institution regardless of physician group. However, non-bone specialists should consider more direct counseling about bone health and consider advisement of weightbearing exercise.


Subject(s)
Osteoporosis, Postmenopausal/therapy , Patient Compliance , Patient Education as Topic/methods , Women's Health , Aged , Aged, 80 and over , Bone Density Conservation Agents/therapeutic use , Combined Modality Therapy , Counseling/methods , Exercise , Female , Health Education/methods , Humans , Middle Aged , Osteoporosis, Postmenopausal/prevention & control , Retrospective Studies , Selective Estrogen Receptor Modulators/therapeutic use , Treatment Outcome , Vitamin D/administration & dosage
20.
J Womens Health (Larchmt) ; 16(7): 1070-5, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17903084

ABSTRACT

Our goal in this paper is twofold. First, it provides a brief overview of the macrotrends in women's health education over the last 25 years. Second, these trends are a backdrop for a discussion of women's health education as exemplified by a detailed review of the curriculum for the Women's Health fellowship at the Cleveland Clinic Foundation. We have termed the underpinning of the curriculum the "leadership triad" consisting of (1) clinical skills, (2) focused research, and (3) interdisciplinary education. These elements are presented in a detailed curriculum for a 2-year fellowship program. We see these elements as fundamental to the Cleveland Clinic's fellowship program, and a useful model for those contemplating or refining their advanced women's health curriculum.


Subject(s)
Community Health Centers/organization & administration , Fellowships and Scholarships , Models, Educational , Women's Health Services/organization & administration , Women's Health , Clinical Competence , Curriculum/standards , Female , Humans , Interdisciplinary Communication , Ohio , Program Evaluation
SELECTION OF CITATIONS
SEARCH DETAIL
...